Inflammatory Disorders - Part A

— —

Rossen Donev (Head of Research, MicroPharm Limited, UK) Rossen Donev (Swansea University, UK)

Inflammatory Disorders - Part A

Rossen Donev (Head of Research, MicroPharm Limited, UK), Rossen Donev (Swansea University, UK), Rossen Donev (Swansea University, UK) , Rossen Donev (Swansea University, UK)

$281.95

Hardback

Not in-store but you can order this
How long will it take?

Availability Information

We source books from suppliers in Australia and overseas. For books we don't currently have in stock, the time it takes to get them from our suppliers can vary widely - from a few days to a few months - so we check each book with each supplier to determine the expected time it will take to be supplied to us.

We then advise you accordingly. If the time taken to get any book is too long for you, you can let us know and we will cancel or adjust your order, and refund as required.

To find out the anticipated arrival time for specific items prior to ordering, please contact us by phone or email:

Phone +61 2 9264 3111, or 1800 4 BOOKS (1800 4 26657) if outside Sydney:
option 1 Abbey's Bookshop (Crime, History, Science, Kids & more) • info@abbeys.com.au
option 2 Language Book Centre (ESL & Foreign Languages) • language@abbeys.com.au
option 3 Galaxy Bookshop (Sci-fi, Fantasy, Romance, Graphic Novels) • sf@galaxybooks.com.au

QTY:

English

Academic Press Inc
24 January 2020

DNA & Genome; Biochemistry; Molecular biology; Cellular biology (cytology)

Series: Advances in Protein Chemistry and Structural Biology

Inflammation is a biological response triggered by different stimuli that has in the body a potentially damaging effect. In certain conditions, such as injury or infection, inflammation is a normal, healthy response. However, inflammatory disorders that result in the immune system attacking the body’s own cells or tissues may cause abnormal inflammation, which results in chronic pain, redness, swelling, stiffness, and damage to normal tissues. Mechanisms involved in promoting a number of different inflammatory disorders and their targeting for therapeutic benefit have been one of the hottest topics in last few decades. The two consecutive volumes (119 and 120) dedicated to this subject cover a wide spectrum of inflammatory disorders, mechanisms that are believed to cause them and different strategies for managing the inflammatory diseases.

Edited by: Rossen Donev (Head of Research MicroPharm Limited UK), Rossen Donev (Swansea University, UK), Rossen Donev (Swansea University, UK), Rossen Donev (Swansea University, UK)
Imprint: Academic Press Inc
Country of Publication: United States
Dimensions: Height: 229mm, Width: 152mm,
Weight: 610g
ISBN: 9780128168448
ISBN 10: 0128168447
Series: Advances in Protein Chemistry and Structural Biology
Pages: 348
Publication Date: 24 January 2020
Audience: Professional and scholarly , Undergraduate
Format: Hardback
Publisher's Status: Active

Rossen Donev received his PhD degree in 1999 from the Institute of Molecular Biology, Bulgarian Academy of Sciences. He did postdoctoral training at Imperial Cancer Research Fund, UK (renamed after the merger with Cancer Research Campaign to Cancer Research UK, London Research Institute) and Cardiff University. In 2007 he was awarded a New Investigator Grant Award from the Medical Research Council (UK) to establish himself as an independent Principle Investigator. In 2010 Dr. Donev was appointed Senior Lecturer at Swansea University. In 2016 Dr. Donev joined MicroPharm Ltd (UK) where currently he is Head of Research. He has published more than 60 research papers, chaired scientific meetings and given invited plenary talks. Rossen Donev has consulted on projects related to development of treatments for neurodevelopmental disorders and cancer therapies. He serves as Editor-in-Chief of the Advances in Protein Chemistry and Structural Biology and on editorial board of several other journals. His research interests include signaling pathways involved in neuropsychiatric disorders and tumor escape from the immune system, and development of therapeutic strategies for their treatment. More recently he has focused on development of immunotherapeutics for non-systemic applications.